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Negative symptoms and progressive gray matter loss. 
Abstract 
Background 
Negative symptoms are perhaps the most disabling feature of schizophrenia.  
Their pathogenesis remains poorly understood and it has been difficult to assess 
their development over time with imaging techniques. 
Aims 
To examine, using tensor-based structural imaging techniques, whether there are 
regions of progressive gray matter volume change associated with the 
development of negative symptoms. 
Method 
43 adolescents at risk of psychosis were examined using magnetic resonance 
imaging and whole-brain tensor-based morphometry at two time points, 6 years 
apart. 
Results 
When comparing the individuals with significant negative symptoms with the 
remaining participants, we identified 5 regions of significant gray matter tissue 
loss over the 6-year period.  These regions included the left temporal lobe, the 
left cerebellum, the left posterior cingulate and the left inferior parietal sulcus.  
Conclusions 
Negative symptoms are associated with longitudinal gray matter tissue loss. The 
regions identified include areas associated with all psychotic symptoms, but also 
include regions uniquely associated negative symptoms. 
Negative symptoms and progressive gray matter loss. 
Introduction 
Schizophrenia remains a major cause of disability, with substantial personal and 
economic costs.  Classically the clinical features of schizophrenia are divided 
into positive symptoms and negative symptoms.  Despite the clinical 
presentation being a mixture of both domains, it is the positive symptoms of the 
disorder which largely form the basis of the operationalised diagnostic criteria 
for schizophrenia (1, 2), which show a response to antipsychotic medication (3) 
and which have proven most tractable to research regarding their 
pathophysiology (4, 5).  However, the negative symptoms of schizophrenia are 
arguably more disabling (6) and as yet there is no form of treatment which can 
be recommended as reliably relieving them (7).  Advances in the development 
of new treatments for negative symptoms are hampered by a lack of 
understanding of their pathophysiology.  A primary reason for this is that 
negative symptoms tend to emerge later rather than earlier in the course of 
schizophrenia (8) making it unusual for them to be ratable in a situation 
uncontaminated by confounding factors (9).  Principal among these confounders 
is antipsychotic medication - it has long been known that negative features may 
be difficult to distinguish from antipsychotic-induced akinesia (10).  Other 
features associated with long-term psychotic illnesses, such as depression (11), 
institutionalization (12) and social isolation (13), also complicate the clinical 
picture in those with longstanding illness.      
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In the Department of Psychiatry in Edinburgh we have focused upon the 
development of psychotic illness and as such have examined populations at 
enhanced risk of schizophrenia. Firstly we studied people where enhanced risk 
was familial (14), where we saw very little in terms of negative symptoms but 
this was not unexpected given the aims of the sample. We have gone on to 
examine individuals at enhanced risk for cognitive reasons (15, 16) and this is 
the sample used here.  It is established that in people who are cognitively 
impaired, the risk of psychosis is higher (17), the onset earlier (18) and that 
negative symptoms are more marked (19) meaning that the current sample is 
particularly suitable for their longitudinal investigation in the absence of the 
confounding factors associated with chronic illness.  A number of cross-
sectional studies have previously reported associations between negative 
symptoms in schizophrenia and tissue loss, in particular gray matter tissue loss 
bilaterally in the insula, superior temporal gyrus and amygdala/hippocampus; as 
well as the left superior temporal gyrus, medial temporal gyrus and occipital 
gyrus (20-22).  Conversely, other studies have reported decreased tissue loss 
associated with negative symptoms (23, 24).  However, the assessment of 
negative symptoms in these studies is potentially confounded by the factors 
mentioned above. Therefore, the ability to assess negative symptoms repeatedly 
and in conjunction with serial scans in a substantial population, largely free from 
neuroleptic medication and at a much earlier age than in most other studies, 
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allows us the unusual opportunity to examine the correlates of negative 
symptoms developing over time in this at risk population.   
 
Methods 
Recruitment 
A full description of the recruitment and design of the Edinburgh Study of 
Comorbidity (from which this sample comes) is published elsewhere (15). In 
brief, local Education Authorities in Scotland were approached for permission to 
approach individual schools.  Of the 19 authorities approached, 18 granted 
permission.  243 schools across Scotland were subsequently approached and 
pupils receiving special educational assistance estimated to be functioning at a 
level consistent with borderline to mild intellectual disability were approached.  
After exclusions, 394 participants were recruited to undergo further study.  After 
screening the group with the childhood behavior checklist (25) and the 
structured interview for schizotypy (26), and sampling the group based on these 
scores to enrich the cohort for participants with higher scores on these measures, 
168 were recruited for the baseline MRI assessment (mean age 15.7 years).  Of 
these, 120 consented to be re-contacted for a follow-up scan 6 years later.  At 
follow-up, we successfully re-contacted 105 families of whom 55 agreed to 
participate in our follow-up imaging.  
 
Clinical Assessment 
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The Clinical Interview Scale (CIS) (27, 28) was used at each of the assessments 
with the examinations being conducted by the same raters on each occasion.  In 
addition, the participants were assessed on the Positive and Negative Syndrome 
Scale (PANSS) (29) rated on the basis of this interview. 
 
Using previously defined thresholds (16), the participants were divided into two 
groups using the scores in the negative symptoms subscale of the PANSS 
representing the presence or absence of morbid negative symptoms in this 
population.  Individuals were allocated to the negative symptoms group if they 
had a score of 3 or above on any of the items of the negative subscale at either 
time-point, with the exception of concrete thinking and lack of spontaneity and 
flow of conversation.  Most participants scored above a 1 on these items by 
virtue of their intellectual impairment therefore we considered a score of 4 to 
represent definite morbidity.  However, none of the participants was allocated to 
the negative symptoms group solely on the basis of their scores in either 
concrete thinking or lack of spontaneity and flow of conversation. All but 6 
participants provided DNA samples to exclude diagnoses of Down Syndrome, 
Fragile X Syndrome or Velocardiofacial Syndrome.  
 
Image acquisition and pre-processing 
The MRI data were collected using a 1.5T GE Signa Horizon HDX (General 
Electric, Milwaukee, WI).  Following midline sagittal localization, the whole 
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brain was imaged by two further sequences: a transverse spin-echo scan 
acquiring both T2- and proton density-weighted images; and a coronal gradient 
echo sequence acquiring 128 high resolution coronal T1-weighted images for 
structural image analysis (time of inversion = 600 msec, echo time = 3.4 ms, flip 
angle = 15°, field of view = 220 mm, slice thickness = 1.7 mm, matrix = 256 × 
192). 
 
The images were converted to ANALYZE 3D format and each image was 
examined for orientation and movement artefacts. The images were analysed in 
SPM5 [www.fil.ion.ucl.ac.uk] running in MATLAB version 7.3 (The 
MathWorks, Natick, MA).  The images were pre-processed using the SPM 
toolset before implementing the staged TBM protocol (30-33) to evaluate the 
gray matter tissue changes between the scans. For all scan acquisitions in this 
study we employed the same scanner, the same sequence and the same head 
coil. Nine participants were excluded from further analysis because of excess 
movement in the scans.  
 
TBM Analysis 
The TBM protocol was implemented by following a staged procedure (31, 32) 
and this was based on the established voxel-wise TBM methodology (30, 33). 
The TBM method is susceptible to participant movement during scan time. As a 
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result of this susceptibility we were not able to use the paired scans from eight 
of the participants. Also, one participant did not complete the scan sequence. For 
each of the participants we recovered grey matter difference images in MNI 
space from the TBM protocol. 
 
The TBM grey matter difference images were smoothed with a 12-mm FWHM 
filter and compared in SPM using the general linear model (GLM). 
Comparisons were made between those with threshold negative symptoms and 
those without such features. Age, inter-scan time interval, sex, full scale IQ and 
PANSS positive symptom score were included in the model as covariates. The 
SPM t-contrast was initially thresholded at t=3.00 (uncorrected) but we report 
results only where the cluster significance corrected for multiple comparisons 
was p<0.05. Removal of the covariates from the SPM cluster analysis increased 
the extent of the reported clusters and established that our analyses including 
covariates were conservative. The TBM-VBM whole brain analysis was 
implemented in MNI standard space and the voxel co-ordinates of the results are 
presented in the same.  The anatomical designations were taken from established 
atlases (34, 35). 
Extracted values for whole brain gray matter volume were also compared to 
establish whether there was a relationship between change in volume and 
symptom states over time. 
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Results 
Description of Participants 
Of the 55 participants scanned at baseline and 6-year follow-up, 46 had paired 
scans of sufficient quality to allow for the TBM analysis.  Three further 
participants were excluded, as their lack of communication at baseline did not 
make it possible to make an assessment of negative symptomatology.  Of these 
43 participants there were 13 females and 30 males, of mean age 15.6 years (s.d. 
1.8) at baseline and 21.6 years (s.d. 1.8) at follow-up, and a mean IQ of 79.6.  
All participants either lived in their own home or in the family home at the time 
of the study.  Of the participants, 5 were in further education, 4 in voluntary 
employment and 20 in paid employment, with the remainder being unemployed.   
 
Table 1 shows the participants’ characteristics as divided into the two clinical 
groupings.  In general, the population was naïve to psychotropic medication but 
two of them were on antipsychotic medication: one who had developed 
operationally-defined schizophrenia since the beginning of the study and who 
was on depot flupentixol, lamotrigine and fluoxetine; the other participant was 
on small doses of amisulpiride and reboxetine for prominent anxiety symptoms. 
Both of these participants were in the negative symptoms group.  A further two 
individuals, both in the non-negative symptom group were taking anti-
depressant medication (sertraline and citalopram).     
Negative symptoms and progressive gray matter loss. 
TABLE 1 HERE 
 
At baseline, the group as a whole had a mean PANSS negative subscale score of 
10.6 (SD=2.6), and at follow-up a mean score of 11.8 (SD=4.6). Figure 1 shows 
the median PANSS negative subscale scores for the two groups at both baseline 
and 6-year follow-up.  The negative symptom scores do not differ significantly 
at baseline (p=0.069), though in the negative symptoms group are significantly 
higher at follow-up (p<0.001).  There was no significant difference in scores of 
observed depression on the Clinical Interview Scale at baseline (p=0.363). 
At baseline, five participants met our threshold for negative feature pathology, 
of whom four had ongoing morbid negative symptoms at follow-up.  In addition 
to these, a further four had developed threshold negative symptoms at 6-year 
follow-up.   
FIGURE 1 HERE 
 
TBM Analysis 
The whole-brain TBM analysis found a number of clusters of significantly 
greater gray matter tissue loss between the scans at baseline and 6-year follow-
up in those with negative symptoms, compared to those who had not.  These 
clusters were in the occipital, inferior parietal and medial temporal lobes, as well 
as the posterior cingulate and the cerebellum.  The significance levels for these 
clusters were calculated using the SPM non-stationary toolbox.   Figures 2a-e 
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show the location and extent of these clusters.  There were no regions of 
significantly greater tissue loss in the participants without negative symptoms 
when compared to the group with those symptoms. 
 
FIGURES 2a – 2e HERE 
 
When the TBM analysis was repeated after excluding the two individuals on 
antipsychotic medication, the left medial temporal gyrus and left cerebellum 
results remained significant. However, the other 3 results no longer remained 
significant.  A third, new cluster in the cerebellum, however, did emerge as 
significant.  The location of the maximal voxel for this cluster (T=3.78) was at 
MNI co-ordinates (-6 -68 -38). 
 
 
Whole Brain Gray Matter Volumes 
 
Figure 3 shows the results from our analysis of whole brain gray matter volumes 
over time.  The differences between the groups are not significant at baseline 
(p=0.881) or follow-up (p=0.858), nor is the change over time (p=0.591). 
 
FIGURE 3 HERE 
 
 
 
Discussion 
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In this study we undertook serial MRI brain imaging of young individuals with 
intellectual limitations, scanning them at mean ages 16 and 22. Between these 
two time points, we found clusters of significantly greater gray matter tissue loss 
in the individuals with prominent negative symptoms compared to those without 
prominent negative symptoms. This included areas of greater tissue loss in the 
posterior cingulate, cerebellum, superior temporal gyrus, medial temporal lobe 
and occipital lobe all on the left hand side. The groups did not differ 
significantly in terms of positive symptoms at either baseline or follow-up, nor 
were any of the participants institutionalised.  The neuroanatomical changes 
over time that we report are therefore likely to relate to the presence of negative 
symptoms in this group and not to other confounding factors.  One potential 
confounder is that although this group is almost completely antipsychotic naïve, 
particularly when compared to other study populations, nonetheless, two of the 
individuals in the negative symptoms group were on antipsychotic medication.  
During further TBM analysis in which we excluded these individuals, two of the 
results remained significant and a new, significant result was found.  We cannot 
know whether the loss of the significant results in the left superior temporal 
gyrus, left occipital lobe and left posterior cingulate is due to the absence of 
antipsychotic effect or merely due to the smaller sample size but we can be sure 
that the development of negative symptoms in a sample uncontaminated by 
antipsychotic medications is associated with tissue loss in the left cerebellum 
and the left medial temporal gyrus. 
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To the authors’ knowledge this is the first longitudinal study in a group at high 
risk of psychosis due to cognitive reasons to relate structural changes to 
increasing negative symptom severity.  Within this group we have previously 
demonstrated gray matter tissue loss in the bilateral medial temporal lobes and 
superior temporal gyri to be associated with significant levels of positive and 
negative symptoms considered together (16) (Table 2).  The results of the 
current study overlap with these previous findings in relation to left medial 
temporal and superior temporal gyrus gray matter loss, but we also identified 
tissue loss in the left posterior cingulate, left cerebellum and left occipito-
parietal region as uniquely associated with negative symptoms. Each of these 
regions has been previously reported to be associated with deficits in social 
cognition, which is known to be impaired in individuals with prominent 
negative symptoms (36).   
 
TABLE 2 HERE 
 
In the current study we reported a large region of tissue loss at 6-year follow-up 
in the left posterior cingulate, which is consistent with the findings of a previous 
cross-sectional study of individuals with schizophrenia (37).  It is possible that 
this finding may help the understanding of the nature of the specific deficits of 
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negative symptoms. The posterior cingulate plays an important role in the 
default mode network (38) and negative symptoms have been previously 
reported to be correlated with decreased connectivity between the posterior 
cingulate and various brain regions including frontal, temporal and midbrain 
structures (39) as well as gray matter tissue loss in the posterior cingulate in 
individuals with schizotypal personality disorder (40). Theory of mind activity 
(the ability to attribute mental states to others) has also been linked to increased 
activity in the posterior cingulate (41) and it is, therefore, of interest that we 
have found significant tissue loss in this area associated with prominent negative 
symptoms, which have been associated with deficits in theory of mind (42).  Our 
finding suggests that this may be an area prone to tissue loss early in the course 
of a developing illness, and that tissue losses may be observable prior to the 
onset of illness and be involved in the aetiology of the disabling and treatment-
refractory negative symptoms. 
 
Our TBM results of tissue loss in the inferior parietal lobule are consistent with 
results from previous studies of negative symptoms in patients with 
schizophrenia (43, 44) and support the idea of the involvement of the inferior 
parietal lobule in the development of schizophrenia.  This is in keeping with the 
hypothesised role of mirror neurons in the inferior parietal lobule with regard to 
social cognition, specifically empathy and understanding the actions and 
intentions of others (45, 46). An alternative possible explanation is that it may 
Negative symptoms and progressive gray matter loss. 
relate to the importance of the parietal lobe in functions which are disturbed in 
schizophrenia such as spatial working memory, language and attention (47).   
 
Although more known for its role in motor co-ordination the cerebellum is 
increasingly recognised as having a variety of non-motor functions including a 
role in social cognition (48). Therefore, our finding of significant tissue loss in 
the left posterior cerebellum, which has previously been shown to be the region 
most associated with non-motor deficits (49), is in keeping with the evidence of 
its role in theory of mind as it relates to negative symptoms.  
 
It is not clear to what degree prominent negative symptoms herald the 
development of schizophrenia, although it has previously been suggested that 
negative symptoms form an earlier, rather than later, part of the prodromal 
illness (50). However, when combined with the finding of Hazlett et al that 
decreased superior temporal gyrus volumes were found in individuals with 
schizophrenia compared to those with schizotypy (51), suggests that prominent 
negative symptoms and gray matter changes may indeed be the forbearer of a 
threshold illness. 
 
Study Limitations 
There are certain limitations to this study.  Firstly, the group with negative 
symptoms are slightly but significantly older than those without.  This is not 
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unexpected as the older subjects are closer to the peak age of onset of 
schizophrenia.  However, as age was included as a covariate in the TBM 
analysis we know that the age difference does not explain our main results.  
Secondly, while it could be suggested that in the negative symptoms group we 
are merely looking at a group with more severe illness, and while in terms of 
negative symptoms this is clearly the case, it is not so in terms of positive 
symptoms which do not differ (see table 1).  It is possible that the negative 
symptoms are a precursor to the development of manifest psychosis but this 
transition has yet to occur. 
The number of individuals with negative symptoms is relatively small and 
confirmation in a larger sample would be desirable.  However, the sample from 
which this group was derived was very large (15, 16) and the opportunity of 
observing the development of negative symptoms over time in a group as large 
as this is unusual.  The significance of the negative symptoms in terms of their 
role as a precursor of the development of schizophrenia cannot be known at this 
stage.  Finally, the inclusion of two individuals in the non-negative group who 
were taking anti-depressants is a possible confounder, although amongst the 
group of 34, of whom the other 32 were medication free, we think it unlikely 
that this was driving the results. In addition the measures of observed depression 
at baseline did not differ significantly between the groups. 
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Conclusion  
The presence and development of negative symptoms in people at high risk of 
schizophrenia for cognitive reasons is related to gray matter tissue loss in brain 
regions associated with social cognition.  Our findings compliment and add to 
those of previous studies in groups at increased risk for other reasons (e.g. 
genetic high risk or clinical high risk). As noted, the pathophysiology of 
negative symptoms has been poorly understood and effective treatments have 
been hard to find.  The results presented here do not overcome these problems 
but may represent a first step towards meaningful understanding of the 
biological underpinnings of these disabling symptoms of schizophrenia. 
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